These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26402801)

  • 1. Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.
    Janczewska E; Flisiak R; Zarebska-Michaluk D; Kozielewicz D; Berak H; Dobracka B; Librant-Suska M; Lojewski W; Jurczyk K; Musialik J; Postawa-Klosińska B; Wroblewski J; Augustyniak K; Dudziak M; Olszok I; Ruszala A; Pisula A; Lapinski T; Kryczka W; Horban A; Dobracki W
    Medicine (Baltimore); 2015 Sep; 94(38):e1411. PubMed ID: 26402801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
    Colombo M; Strasser S; Moreno C; Abrao Ferreira P; Urbanek P; Fernández I; Abdurakmonov D; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Lonjon-Domanec I; Wedemeyer H
    J Hepatol; 2014 Nov; 61(5):976-83. PubMed ID: 24946280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
    Di Bisceglie AM; Sulkowski M; Gane E; Jacobson IM; Nelson D; DeSouza C; Alves K; George S; Kieffer T; Zhang EZ; Kauffman R; Asmal M; Koziel MJ
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):761-73. PubMed ID: 24901821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
    Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS
    Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
    Muir AJ; Poordad FF; McHutchison JG; Shiffman ML; Berg T; Ferenci P; Heathcote EJ; Pawlotsky JM; Zeuzem S; Reesink HW; Dusheiko G; Martin EC; George S; Kauffman RS; Adda N
    Hepatology; 2011 Nov; 54(5):1538-46. PubMed ID: 22045671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.
    Silva GF; Villela-Nogueira CA; Mello CE; Soares EC; Coelho HS; Ferreira PR; Ruiz FJ;
    Braz J Infect Dis; 2014; 18(1):48-52. PubMed ID: 24055310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
    Kumada H; Suzuki F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Fujiyama S; Ito T; Itoh Y; Tamura E; Ueki T; Ishikawa H; Hu W; McPhee F; Linaberry M; Hughes E
    J Gastroenterol Hepatol; 2016 Jan; 31(1):14-22. PubMed ID: 26252875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D
    Med Pregl; 2006; 59(9-10):415-9. PubMed ID: 17345816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
    Rubin RA; Russo MW; Brown KA; Fontana RJ; Levitsky J; Vargas H; Yoshida EM; Brown RS
    Exp Clin Transplant; 2018 Apr; 16(2):182-190. PubMed ID: 27855589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.
    Ozeki I; Akaike J; Karino Y; Arakawa T; Kuwata Y; Ohmura T; Sato T; Kamiya N; Yamada I; Chayama K; Kumada H; Toyota J
    J Gastroenterol; 2011 Jul; 46(7):929-37. PubMed ID: 21556829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
    Hayashi N; Okanoue T; Tsubouchi H; Toyota J; Chayama K; Kumada H
    J Viral Hepat; 2012 Feb; 19(2):e134-42. PubMed ID: 22239511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
    Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N
    J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.
    Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N
    J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.
    Shiffman ML; Di Bisceglie AM; Lindsay KL; Morishima C; Wright EC; Everson GT; Lok AS; Morgan TR; Bonkovsky HL; Lee WM; Dienstag JL; Ghany MG; Goodman ZD; Everhart JE;
    Gastroenterology; 2004 Apr; 126(4):1015-23; discussion 947. PubMed ID: 15057741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.